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Summary: L-selectin (CD62L) is widely used to distinguish non-activated (L-selectin+) from 
activated (L-selectin–) T lymphocytes, but the pathophysiological role of L-selectin 
downregulation is poorly understood. In this report, we show that ADAM17-dependent 
proteolytic shedding of L-selectin is required to synchronize the rapid expansion of cytotoxic 
T-cells.  
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Abstract   
L-selectin on T-cells is best known as an adhesion molecule that supports recruitment of 
blood-borne naïve and central memory cells into lymph nodes. Proteolytic shedding of the 
ectodomain is thought to redirect activated T-cells from lymph nodes to sites of infection. 
However, we have shown that activated T-cells re-express L-selectin before lymph node 
egress and use L-selectin to locate to virus-infected tissues.  Therefore, we considered other 
roles for L-selectin proteolysis during T cell activation.  In this study, we used T cells 
expressing cleavable or non-cleavable L-selectin and determined the impact of L-selectin 
proteolysis on T cell activation in virus-infected mice. We confirm an essential and non-
redundant role for ADAM17 in TCR-induced proteolysis of L-selectin in mouse and human T 
cells and show that L-selectin cleavage does not regulate T cell activation measured by CD69 
or TCR internalisation. Following virus infection of mice, L-selectin proteolysis promoted early 
clonal expansion of cytotoxic T cells resulting in an 8-fold increase over T cells unable to 
cleave L-selectin. T cells unable to cleave L-selectin showed delayed proliferation in vitro 
which correlated with lower CD25 expression. Based on these results, we propose that 
ADAM17-dependent proteolysis of L-selectin should be considered a regulator of T-cell 
activation at sites of immune activity.  
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Introduction 
L-selectin delivers naïve and central memory T-cells from the bloodstream into lymph nodes 
to survey antigen presenting cells (APC) for peptide-MHC complexes. It has long been known 
that L-selectin is proteolytically shed from the T-cell surface within hours following engagement 
of the T-cell receptor (TCR)1 and that lack of L-selectin expression is a characteristic feature 
of effector and effector memory T cells inside inflamed and infected tissues2. These findings 
have suggested that downregulation of cell surface L-selectin is required to prevent activated 
T-cells re-entering lymph nodes from the bloodstream and allow entry into infected and 
inflamed tissues.  However, we have shown that, following downregulation of L-selectin by 
peptide-MHC complexes inside lymph nodes, L-selectin is fully re-expressed on virus-specific 
early effector CD8+ T cells before they egress lymph nodes3. Moreover, re-expressed L-
selectin is essential for circulating effector T cells to home to and clear virus from infected 
organs.  If L-selectin downregulation is not required to re-direct activated T-cells to sites of 
inflammation, what is the role of L-selectin proteolysis during T cell activation?  
 
Cross-linking of L-selectin primes T-cells for antigen-induced proliferation4 and controls 
important effector functions such as superoxide production5, colony-stimulating factor 1 
release6 and lytic activity7. The cytoplasmic tail of L-selectin is phosphorylated by adaptor 
proteins and non-receptor kinase-complexes following ligand engagement and 
phosphorylation is linked to effector activities5,6.  It is reasonable to propose that TCR-induced 
proteolytic shedding of the ectodomain of L-selectin will abrogate signalling initiated and 
sustained by ligand binding.  However, TCR engagement also stimulates phosphorylation-
dependent binding of protein kinase C isozymes ι, θ, and α to the cytoplasmic tail of L-selectin8.  
It is, therefore, possible that the transmembrane fragment of L-selectin with bound signalling 
complexes left after TCR-induced shedding of the ectodomain has the potential to move into 
different cellular compartments to propagate, rather than abrogate, L-selectin-dependent 
signalling.   
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The metalloproteinase disintegrins ADAM10 and ADAM17 have emerged as important 
enzymes controlling ectodomain shedding of multiple substrates in haemopoietic and non-
haemopoietic cells, particularly in response to cellular activation by ionomycin and phorbol 
esters respectively9.  Studies of mice with selective inactivation of adam17 in leucocytes, T 
cells or B cells have shown a dominant role for ADAM17 in shedding of L-selectin stimulated 
by phorbol esters9-13. Moreover, ADAM17 deficient T cells are unable to shed L-selectin early 
after activation by anti-CD3 antibodies13.  However, ADAM17 deficient T cells are not ideal for 
studying the role of L-selectin proteolysis in T cell activation for several reasons. Firstly, 
enzymes other than ADAM17 cleave L-selectin since plasma levels of shed L-selectin are not 
altered in mice selectively deficient in leucocyte ADAM1711. Secondly, substrates of ADAM17 
other than L-selectin that are proteolytically shed following TCR activation have already been 
shown to control T cell proliferation and/or differentiation, such as IL6Rα13 and LAG-314.  Thus, 
although L-selectin may not be proteolyzed, the lack of proteolysis of other important 
regulators of T cell activation may mask any role for L-selectin proteolysis in ADAM17 null T 
cells. 
 
To study the role of L-selectin proteolysis directly, we exploited T-cells expressing a 
metalloprotease cleavage-resistant mutant of L-selectin to determine the impact of TCR-
induced proteolysis of L-selectin on T cell activation during virus infection. Our data show that 
TCR-induced proteolysis of L-selectin by ADAM17 did not affect early activation of T cells 
measured by CD69 expression but promoted early clonal expansion of cytotoxic T-cells which 
correlated with upregulation of CD25. 
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Results and Discussion 
ADAM17 is essential for TCR-induced ectodomain proteolysis of L-selectin 
We aimed to study the role of L-selectin proteolysis in controlling T cell activation during virus 
infection. Therefore, we started by determining the role of ADAM17 in ectodomain shedding 
of L-selectin in T cells following activation by virus derived peptide-MHC complexes on antigen 
presenting cells.  Embryos die in utero in C57BL/6 (B6) mice lacking ADAM1710. However, 
radiation chimeras reconstituted with ADAM17 deficient haempoietic stem cells are viable11. 
To generate mice in which adam17 is selectively inactivated in lymphocytes, lethally irradiated, 
recombination activation gene-1 deficient (RAG-1-/-) mice were injected with day 17 foetal liver 
cells from either ADAM17 deficient (ADAM17∆Zn/∆Zn) or ADAM17 sufficient (ADAM17WT) 
embryos (Fig.1A).  Donor-derived lymphocytes were analysed 12 weeks later for spontaneous 
(constitutive) and phorbol-ester induced shedding of L-selectin to confirm ADAM17 status.  
Lymphocyte ADAM17 was not essential for reconstitution of lymphocytic lineages as found 
previously using ADAM17 deficient haemopoietic cell chimeric mice11.  Lymph node 
cellularities in ADAM17 sufficient (ADAM17WT) and ADAM17 deficient (ADAM17∆Zn/∆Zn) 
chimeras were 26 ± 6 x 106 and 23 ± 7 x 106 respectively and T:B lymphocyte ratios, 1.8 ± 0.3 
and 2.1 ± 0.2 respectively. ADAM17 did not affect the frequency of L-selectin+ T-cells in lymph 
nodes (Fig. 1D) or L-selectin levels per cell (ADAM17∆Zn/∆Zn: ADAM17WT, MFI of 1.20 ± 0.29; 
n = 6). Low levels of constitutive shedding from isolated lymph node lymphocytes15 is not 
dependent on ADAM17 since the levels of soluble and cell surface L-selectin were not affected 
by lack of ADAM17 expression (Fig. 1D, E). However, the hydroxamic acid based 
metalloproteinase inhibitor Ro 31-9790 completely blocked release of soluble L-selectin from 
both ADAM17WT and ADAM17∆Zn/∆Zn lymphocytes (Fig. 1 E) and increased the fraction of L-
selectin+ T-cells by 15.5 ± 4.0 % for ADAM17WT and 19.0 ± 2.0 % for ADAM17∆Zn/∆Zn (n = 6).  
The role of ADAM17 in controlling cell surface expression of L-selectin appears to depend on 
the T cell source as well as the mouse model; radiation chimeras reconstituted with ADAM17 
deficient haemopoietic stem cells showed 3-fold higher cell surface levels of L-selectin on 
peripheral blood T cells11, whereas inactivation of adam17 did not increase L-selectin levels 
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on T cells isolated from lymphoid tissues13, as we have found. However, ADAM17 was 
essential for phorbol ester induced shedding of L-selectin in T cells as reported previously10,13.  
Phorbol 12-myristate 13-acetate (PMA) had no effect on cell surface or soluble L-selectin 
levels in ADAM17-deficient T-cells, whereas cell surface L-selectin was reduced from 72.7 ± 
3.1 to 7.9 ± 1.7 % (n = 4) (Fig. 1D) and soluble L-selectin increased 2-fold in ADAM17-sufficient 
T-cells (Fig. 1E).  Substituting the juxtamembrane L-selectin cleavage site with the 
homologous region of P-selectin (L∆P) completely inhibited constitutive and PMA-induced L-
selectin shedding in isolated lymphocytes (Fig. 1F, G) as reported previously15, indicating that 
ADAM17-dependent and ADAM17-independent L-selectin cleavage occurs within this region.  
L-selectin is shed from lymphocytes as well as other types of leucocyte15-17 and is detectable 
in the blood of naïve mice. To determine if ADAM17 controls shedding of L-selectin in mice, 
we measured soluble L-selectin in peripheral blood.  To avoid detection of soluble L-selectin 
from host-derived leucocytes, we used L-selectin-/- mice as hosts for ADAM17 deficient or 
ADAM17 sufficient stem cells (Fig 1B; see Methods). In L-selectin-/- chimeras, the source of 
soluble, shed L-selectin in blood is restricted to the progeny of injected stem cells. Twelve 
weeks after reconstitution, circulating levels of soluble L-selectin were not statistically 
significantly different in ADAM17 sufficient and ADAM17 deficient L-selectin knockout  
(CD62L-/-) chimeras (Fig. 1H). Similar findings have been reported in ADAM17 sufficient and 
ADAM17 deficient B6 radiation chimeras11. These results demonstrate clearly that soluble L-
selectin is not generated by ADAM17 expressed by leucocytes, however, it is dependent on 
metalloproteinase-dependent cleavage as shown by its’ absence in L∆P mice (Fig. 1H).  The 
possibility that ADAM17 on stromal cells generates soluble L-selectin was addressed using a 
different mouse strain (Fig. 1C).  ADAM17 deficiency does not cause embryonic lethality in 
the DBA strain and mice survive to ~3 weeks of age. This enabled us to determine if L-selectin 
is shed in the complete absence of ADAM17 from leucocytes as well as stromal cells. Although 
L-selectin levels were lower in 3-week old mice, the levels were not significantly different in 
ADAM17 sufficient and ADAM17 deficient DBA mice (Fig. 1H). These findings show clearly 
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that, in the absence of ADAM17 on leucocytes, ADAM17 on stromal cells does not generate 
soluble L-selectin. Moreover, these data show that metalloproteinases other than ADAM17 
can generate soluble L-selectin in mice. In vitro studies have shown that ADAM10 cleaves L-
selectin in cell lines lacking ADAM179 and that ADAM10 is constitutively active in T cells14,18. 
To determine if ADAM10 substitutes for ADAM17 in T cells, we tested tissue inhibitor of 
metalloproteinase (TIMP)-119 and TIMP-320, both of which block ADAM1021. Neither TIMP-1 
nor TIMP-3 blocked constitutive metalloproteinase dependent shedding of L-selectin from 
ADAM17-deficient T-cells (Fig. 1I), although TIMP-3 inhibited PMA-induced shedding from 
ADAM17 sufficient mouse T cells22.  The relationship between plasma L-selectin and L-
selectin spontaneously shed from isolated T cells is not completely understood11,23.  We have 
shown that soluble and cell surface L-selectin are linked in transgenic mice expressing 
different levels of L-selectin at the T cell surface24, but the stimulus for shedding of L-selectin 
from T cells in naïve mice is not known.  Together, our studies show that blood levels of L-
selectin in mice are completely independent of ADAM17 expressed either by leucocytes or by 
stromal cells. Furthermore, constitutive shedding in isolated T-cells is independent of ADAM17 
and ADAM10.  Further studies will be required to identify the sheddase or sheddases 
responsible and determine how their activities are regulated. 
 
To determine the role of ADAM17 in TCR induced L-selectin shedding in mice, we used the 
bacterial superantigen staphylococcus enterotoxin B (SEB), which selectively activates T-cells 
expressing the Vβ8+ chain of the TCR25. L-selectin was downregulated on Vβ8+ but not Vβ8– 
T-cells in B6 mice as well as ADAM17-sufficient RAG-1-/- chimeras (Fig. 2A–D). In contrast, 
SEB did not downregulate L-selectin on ADAM17-deficient Vβ8+ T-cells in RAG-1-/- chimeras 
(Fig. 2A, B).  Vβ8+ T-cells in transgenic L- selectin (LΔP) mice did not shed L-selectin in 
response to SEB (Fig. 2C, D); the slight trend to increased expression over Vβ8– T-cells may 
reflect activity of the heterologous promoter which drives transgene expression.  These results 
demonstrate clearly a non-redundant role for T cell expressed ADAM17 in L-selectin 
ectodomain proteolysis following TCR activation. 
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TCR-induced shedding of L-selectin in human T cells was studied using L-selectin deficient 
Molt-3 T-leukemic cells, transduced to express an HLA-A2-restricted HIV-1 Gag SLYNTVATL 
(SLY)-specific TCR (868) and either wildtype human L-selectin (L-selectin) or cleavage 
resistant human L-selectin (ΔM-N)26.  Constitutive shedding of wildtype L-selectin, but not ΔM-
N-L-selectin, was evident by lower expression of L-selectin in unstimulated cells (Fig. 2E). 
Engagement of the 868 TCR with SLY peptide-MHC stimulated dose-dependent 
downregulation of L-selectin by 30-40%, but not ΔM-N-L-selectin (Fig. 2E). The roles of 
ADAM17 and ADAM10 in TCR-induced L-selectin shedding in human cells were dissected by 
comparing the hydroxamate-based metalloproteinase inhibitor GW280264X (GW) which 
inhibits both ADAM17 and ADAM10 and GI254023X (GI) which is 100-fold more selective for 
ADAM10 than ADAM1727. These compounds have previously been used to dissect the roles 
of ADAM10 and ADAM17 in PMA-induced shedding of L-selectin in mouse T cells12. GW 
completely blocked TCR-induced L-selectin shedding at 3µM, whereas 3µM GI had no effect 
(Fig. 2F).  The lack of effect of GI at equivalent doses to effective levels of GW indicates that 
ADAM10 does not substitute for ADAM17 in TCR induced shedding of L-selectin. However, 
GW and GI inhibit a number of other metalloproteinases27, some of which have been shown 
to shed L-selectin28. Therefore, GW cannot be used in isolation to measure ADAM17 activity.   
An essential role for ADAM17 in TCR-induced shedding of L-selectin in human T cells was 
demonstrated using the inhibitory anti-ADAM17 antibody D1(A12)29 which completely inhibited 
L-selectin shedding at ≥ 300 nM (Fig. 2 G). Collectively, these results demonstrate an essential 
role for ADAM17 in TCR-induced L-selectin shedding in T-cells. A role that cannot be 
substituted for either by ADAM10 or by the constitutively active metalloproteinase in T cells 
reported. There was no evidence of cross-talk between ADAM17-dependent L-selectin 
proteolysis and early T-cell activation, since TCR downregulation was independent of GW or 
ΔM-N-L-selectin expression (Fig. 2H; data not shown). 
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Ectodomain proteolysis of L-selectin controls rapid clonal expansion of cytotoxic T-
cells  
CD8+ T-cells differentiate into cytotoxic T-cells (CTLs) and initiate rapid clonal expansion in 
lymphoid organs of mice during the first 24–48h following virus infection30. We have shown 
that TCR-induced shedding of L-selectin occurs in lymph nodes draining the site of virus 
administration within 24-48 hours3. Therefore, we started by using mouse models of virus 
infection to determine whether L-selectin proteolysis regulates clonal expansion of cytotoxic 
T-cells in vivo. Naïve CD8+ T cells expressing H2Db restricted influenza A nucleoprotein 
peptide 366-374 (NP68)-specific TCR (F5) and either wildtype L-selectin (F5/B6) or shedding-
resistant L-selectin (F5/L∆P) were CFSE labelled and adoptively transferred into naïve B6 
mice. After 24h, recombinant vaccinia virus expressing NP68 (vaccNP) was injected 
intraperitoneally, and the draining mediastinal lymph nodes harvested on days 1 and 2 post-
infection for analysis of donor CD8+ T-cell activation and proliferation (Fig. 3A). L-selectin 
proteolysis did not affect CD8+ T-cell priming in response to stimulation with peptide-MHC 
complexes on antigen-presenting cells, as CD69 was upregulated at day 1 post-infection and 
downregulated at day 2 post-infection to a similar extent on F5/B6 and F5/LΔP CD8+ T-cells 
(Fig. 3B). Dilution of CFSE was not detectable in either F5/B6 or F5/LΔP CD8+ T-cells until 
day 2 post-infection. However, wildtype CD8+ T-cells proliferated more than CD8+ T cells 
expressing L∆P L-selectin (Fig. 3C), as evident by CFSE dilution and the significantly higher 
division index for F5/B6 CD8+ T-cells relative to F5/L∆P CD8+ T-cells (Fig 3D). The increased 
dilution of CFSE was reflected by a striking 8-fold increase in the number of F5/B6 CD8+ T-
cells in comparison with F5/L∆P T-cells in the mediastinal lymph nodes between days 1 and 
2 post-infection (Fig. 3E, F). Neither F5/B6 nor F5/LΔP CD8+ T-cells proliferated in the 
absence of vaccNP inoculation. Activated T-cells exit mediastinal lymph nodes on day 3 after 
vaccNP infection and become detectable in the peripheral blood and at sites of virus 
replication3. Accordingly, we did not analyse CD8+ T-cell in the mediastinal lymph nodes 
beyond day 2 post-infection. 
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To dissect mechanisms linking L-selectin proteolysis to T cell proliferation, F5/B6 and F5/L∆P 
T cells were stimulated with NP68-pulsed irradiated antigen-presenting cells in vitro and 
analyzed up to 7 days following activation. The kinetics and extent of CD69 upregulation in 
the first 24h after TCR engagement were similar in T-cells expressing wildtype or L∆P L-
selectin, indicating that ADAM17-mediated L-selectin proteolysis is not required for TCR signal 
transduction (Fig. 4 A, B). To assess the role of L-selectin shedding in T-cell proliferation, 
F5/B6 and F5/L∆P CD8+ T-cells were labelled with CFSE and cultured with peptide-pulsed 
antigen-presenting cells and exogenous IL-2. After 4 days, wildtype CD8+ T-cells proliferated 
more than CD8+ T cells expressing L∆P L-selectin (Fig. 4C), as evident by CFSE dilution and 
the significantly higher division index for F5/B6 CD8+ T-cells relative to F5/L∆P CD8+ T-cells 
(Fig. 4D). Comparison of CFSE dilution profiles showed a transient delay in proliferation that 
was restricted to a subpopulation of F5/L∆P CD8+ T-cells, which resolved by day 5.  
F5/B6 and F5/L∆P CD8+ T-cell cultures were supplemented equally with exogenous IL-2 on 
the second day after stimulation and we have reported that F5/B6 and F5/L∆P CD8+ T-cells 
synthesise similar levels of IL-2 in vitro3. Therefore, we reasoned that differences in 
proliferation were not related to cytokine levels and instead determined the role of receptors 
for IL-2. We started by analysing the expression of CD25 (IL-2Rα) which together with CD127 
(IL-2Rβ) and CD132 (IL-2Rγ) forms a high affinity receptor for IL-231. In the absence of 
activation, ~ 2% of F5/B6 and F5/L∆P CD8+ T-cells expressed CD25. The frequency of CD25 
expressing F5/B6 CD8+ T-cells started to increase by day 2 following peptide-MHC stimulation 
and increased to maximal levels by day 4, when ~90 % of cells expressed CD25. CD25 
expressing F5/L∆P CD8+ cells also increased between days 2 and 4 following TCR-activation. 
However, the frequency of CD25 expressing F5/L∆P CD8+ was consistently lower than CD25+ 
F5/B6 T cells at days 2, 3 and 4 and the difference was statistically significant at day 3 when 
60 % of F5/B6 CD8+ T-cells expressed CD25, whereas only 38 % of F5/L∆P CD8+ T-cells 
expressed CD25 (Fig. 4E, F). Differences in CD25 expression between F5/B6 and F5/LΔP T 
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cells were no longer seen at day 5 when ~90 % of both cell types expressed CD25.  The delay 
in proliferation of F5/L∆P CD8+ T-cells correlated with reduced expression of CD25.  
Metalloproteinases such as matrix metalloproteinase-9 (MMP9) have been shown to regulate 
CD25 expression on tumour infiltrating T cells in clinical cancers32. We tested whether the 
level of CD25 on activated F5 T cells is regulated by metalloproteinases and included GW or 
GI for 24 hours from day 2 to day 3 of T cell activation when CD25 expression is upregulated. 
CD25 expression was not affected by GW or GI (MFIs: Control 637 ± 3; GI: 598 ± 30; GW: 
672 ± 56, n=3) showing no role for ADAM17 or ADAM10 in controlling CD25 expression by 
activated CD8+ T cells.  The lack of effect of either GW or GI also eliminates roles for MMP3, 
MMP9 or MMP13 which are also inhibited by GI and/or GW27 in controlling CD25 expression 
in activated CD8+ T cells.  The impact of a delay in proliferation of F5/L∆P CD8+ T-cells as 
shown by CFSE dilution was detectable on day 4 and maintained during the subsequent rapid 
expansion of T cells by the increased numbers of F5/B6 over F5/L∆P CD8+ T-cells of 4.9-fold, 
5.5-fold and 3.7- fold on days 4, 6 and 7 respectively following stimulation. 
Our findings of earlier and increased clonal expansion of isolated T cells able to shed L-
selectin are consistent with findings in virus-infected mice. The earlier clonal expansion of 
CD8+ T-cells in mice is striking in comparison with peptide-MHC stimulated T cell proliferation 
in vitro. This is due, in part, to the experimental design in that isolated F5 CD8+ T cells are 
stimulated by cognate peptide and supplemented with cytokines on day 2 after T cell 
stimulation whereas in lymph nodes, F5 CD8+ T cells are supplemented with cytokines derived 
from polyclonal CD4+ T helper cells also activated by virus. Other contributing factors may be 
the induction of chemokine dependent recruitment of T cells inside lymph nodes which 
optimizes T cell priming by virus-infected antigen presenting cells33 and/or differences in 
peptide loading onto MHC by infectious virus.  Collectively, our findings demonstrate that 
ADAM17-dependent, L-selectin proteolysis following engagement of the TCR plays a critical 
role in early clonal expansion of cytotoxic CD8+ T-cells, potentially via regulation of CD25 
expression. Further studies will be required to determine how L-selectin cleavage affects 
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CD25 expression and proliferation in T cells.  The dominant role of L-selectin in controlling 
leucocyte adhesion has focused attention on its adhesive function. The cytoplasmic tail of L-
selectin binds to a number of structural and signalling proteins known to regulate leucocyte 
adhesion34,35. The soluble fragment of L-selectin retains ligand binding activity and acts as an 
adhesion buffer by limiting leucocyte recruitment from the bloodstream16.  The impact of L-
selectin cleavage of T cell proliferation could be an indirect effect of altered binding to antigen 
presenting cells which express PSGL-136, a cognate ligand for L-selectin, resulting in altered 
transmission of co-stimulatory signals to T cells.  However, TCR engagement stimulates 
phosphorylation-dependent binding of protein kinase C isozymes ι, θ, and α to the cytoplasmic 
tail of L-selectin8, some of which are known to regulate T cell activation.  It is, therefore, 
possible that the membrane associated cleaved fragment directly stimulates T cell proliferation 
or that non-cleaved L-selectin inhibits T cell proliferation due to lack of translocation to a 
different membrane compartment. Further experiments will be required to pin-point the 
underlying mechanism or mechanisms.  
 
The presented findings predict that, in the absence of L-selectin shedding, reduced clonal 
expansion of cytotoxic T cells in lymph nodes will affect the kinetics of virus clearance in 
peripheral tissues if the number of cytotoxic T cells generated is insufficient to kill virus-infected 
cells.  We have already demonstrated the pathophysiological importance of L-selectin 
proteolysis in memory CD8+ T cells in that T cells unable to shed L-selectin show reduced viral 
clearance37. The delayed clonal expansion of cytotoxic T cells unable to shed L-selectin 
reported here is a potential explanation for reduced clearance of virus by memory T cells 
unable to shed L-selectin.  Mouse T cells expressing a different construct of L-selectin in which 
the membrane proximal region of E-selectin is knocked into wildtype L-selectin, have been 
shown to resist shedding stimulated by anti-CD3 antibodies but the impact on T cell 
proliferation was not determined17.  Interestingly, T cells unable to shed L-selectin due to a 
deficiency in ADAM17 showed no deficit in CD4+ or CD8+ T-cell activation following bacterial 
infection13. This suggests that ADAM17-dependent proteolysis of L-selectin may not control T 
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cell activation or function during bacterial infection. However, other ADAM17 substrates known 
to control T cell activation such as IL6Rα13 or LAG-314 will not be proteolyzed in ADAM17 null 
T cells and may mask a role for L-selectin proteolysis in T cell activation. Our approach using 
T-cell specific cleavable or non-cleavable L-selectin is a conceptual advance that overcomes 
the severe limitations of targeting ADAM17 in T-cells where the cleavage of up to 70 proteins 
will be dysregulated, some of which are known to control T-cell activation, thus allowing the 
analysis of ADAM17 dependent proteolysis of L-selectin in heath and disease.   
 
In the T cell lineage, L-selectin identifies naïve and central memory T cells which both have 
high proliferative potential38. L-selectin also marks a stem-like population in the CD8+ and NKT 
lineages which show renewal and persistence39,40.  Apart from lymph node homing, the 
contribution of L-selectin to the biology of T cells, has not been extensively studied. However, 
it has long been known that there is significant cross-talk between L-selectin and TCR 
signalling but the physiological relevance of TCR-induced downregulation of L-selectin during 
T-cell activation has remained elusive. Based on our findings, the potential of ADAM17 
dependent L-selectin proteolysis in regulating the activation of other types of leucocyte in 
disease settings, even in cells are recorded as L-selectin negative at the time of analysis due 
to active ADAM17, and should be considered. In this manuscript we present the novel concept 
that proteolysis of L-selectin by ADAM17 controls T-cell activation inside lymphoid tissues and 
present data to show this both in isolated T-cells and in mice. Our results show that cleavage 
of L-selectin by ADAM17-dependent proteolysis promotes early clonal expansion of cytotoxic 
T-cells. On this basis, we propose that ADAM17 dependent L-selectin proteolysis should be 
considered as a regulator of T-cell activation at sites of immune activity.   
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Materials and Methods  
Mice 
RAG-1-deficient mice were bred at the Frances Crick Institute (London, UK). C57BL/6 (B6) 
mice were purchased from Harlan or Charles River Laboratories. ADAM17+/ΔZn heterozygous 
mice were provided by Dr Jacques Peschon and Dr Roy Black (Immunex) and C57BL/6 L-
selectin knockout mice by Professor Tom Tedder.  L-selectin knockout (CD62L-/-) mice 
expressing a shedding-resistant form of L-selectin as a transgene on either polyclonal T-
lymphocytes (LΔP) or CD8+ T-cells co-expressing F5 TCR (F5/LΔP) have been described15. 
All other mice were bred in house. 
ADAM17 sufficient and ADAM17 deficient chimeras 
Embryos were collected at e16.5–17 after timed matings of ADAM17+/ΔZn heterozygous mice, 
in which the zinc-binding domain of ADAM17 was replaced with neomycin 10 and genotyped 
for the zinc-binding domain and the neomycin gene using 15 µl of tail tip DNA in separate PCR 
reactions. Primers (25 pM) for the zinc-binding domain (forward, 5´ CCA CGA GAA TAA TAA 
GGT ATG TCT 3’; reverse, 5´ AGG AAG AGG AAG GGG ACT A 3´; 360 bp product) or 
neomycin (forward, 5´ GGA GAG GCT ATT CGG CTA TG 3´; reverse, 5´ CAG GAG CAA 
GGT GAG ATG A 3´; 281 bp product) were mixed with 200 µl of dNTPs and 1.25 U Taq 
polymerase in 50 µl of PCR buffer. Reactions were denatured for 5 minutes at 94 C, DNA 
amplified over 34 thermocycles (1 minute at 94 C, 1 minute at 59 C, and 30 seconds at 72 
C). PCR products were separated on 3 % agarose gels containing 0.5 µg/ml ethidium bromide 
and visualized. ADAM17-deficient (ADAM17ΔZn/ΔZn) embryos were identified by the the 
presence of the neomycin gene, wildtype (ADAM17+/+) embryos were identified by the 
presence of the zinc-binding domain, and heterozygous (ADAM17+/ΔZn) embryos were 
identified by the presence of both the zinc-binding domain and the neomycin gene. In some 
experiments, eyelid fusion was used to phenotype embryos (open eyelids: ADAM17 deficient; 
closed eyelids: wildtype and ADAM17 heterozygotes).  Fetal liver cells were isolated from 
ADAM17ΔZn/ΔZn embryos or pooled wildtype ADAM17+/+ and heterozygous ADAM17+/ΔZn 
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littermates by passing through 70 µm cell strainers, washed in PBS, resuspended in FCS 
containing 10 % DMSO, and stored at –80 C. Thawed cells (5–10 x 105) were washed, 
resuspended in PBS and injected intravenously into sublethally irradiated (5–6 Gy) C57BL/10 
RAG-1-/- or C57BL/6 L-selectin-/- mice. Chimeric mice were tested for ADAM17 based on 
susceptibility or resistance to PMA-induced shedding of L-selectin on peripheral blood T-
lymphocytes15. Lymphocytes generated from genotyped (n = 6) and phenotyped (n = 12) 
ADAM17ΔZn/ΔZn embryos failed to shed L-selectin in response to PMA 10. PMA-induced 
shedding was equivalent in ADAM17 sufficient lymphocytes (ADAM17+/+ and ADAM17+/ΔZn) 10 
and data generated using ADAM17+/+ and ADAM17+/ΔZn lymphocytes were pooled and 
described as ADAM17WT lymphocytes.  All experiments were conducted according to 
institutional guidelines and UK Home Office regulations using age/sex-matched mice aged 8–
12 weeks. The genotypes of mouse strains are summarized in Supplementary Table 1. 
 
L-selectin-expressing lymphoid cells  
Peripheral lymph nodes (axillary, brachial, and inguinal) from ADAM17 chimeras, LΔP, 
F5/LΔP, B6, or F5/B6 mice, all aged 12–16 weeks, were collected into Ca2+/Mg2+-free PBS on 
ice, passed through 70 µm cell strainers, and washed in PBS. Lymphocytes were collected by 
centrifugation at 250 g. CD8+ T-cells co-expressing the F5 transgenic TCR and either wildtype 
L-selectin (F5/B6) or shedding-resistant L-selectin (F5/LΔP) were isolated from pooled spleen 
and peripheral lymph node samples by negative selection using a CD8α+ T-cell isolation kit 
with LS columns (Miltenyi Biotec). The genotypes of mouse T-cells are summarized in 
Supplementary Table 2. 
 
Human L-selectin negative MOLT-3 acute lymphoblastoid T-cells (ATCC CRL-1552), were 
sequentially transduced with lentiviral particles isolated from transiently transfected 293T cells 
to express an HIV-1 Gag SLYNTVATL-specific TCR (868) 41 and either wildtype L-selectin or 
shedding-resistant ∆M-N human L-selectin 26. Full-length and ∆M-N-L-selectin were amplified 
using PfuUltra II Fusion HS DNA Polymerase (Agilent), and the PCR product was cleaved with 
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BamHI and XhoI before ligation into BamHI-linearized pSxW using In-fusion (Clontech). 
Briefly, 2 x 107 293T cells were incubated overnight in T175 flasks (Thermo Fisher Scientific). 
The following day, medium was replaced with 12 ml of DMEM supplemented with 10 % FCS 
(pH 7.9). Transfection mix (3 ml) containing 60 μg of pSxW, 60 μg of pCMVΔ8.91, 30 μg of 
pMD2G 42, and 0.15 M CaCl2 in serum-free DMEM (pH 7.1) was added dropwise, and the 
flasks were incubated overnight at 37 C. Medium was replaced after 24 hours with 20 ml of 
fresh DMEM 10 % FCS. Lentiviral particles were collected at 48 and 72 hours post-
transfection. Supernatants were ultracentrifuged using a Sorvall SW28 rotor at 26,000 rpm for 
2h, concentrated 10-fold, and stored at –80 C. MOLT-3 cells (0.5 x 10⁶) were transduced with 
concentrated lentiviral particles and 4 μg/ml Polybrene (Sigma-Aldrich). Cells were analyzed 
for transgene expression by flow cytometry 48h after transfection. Leukemic T-cell clones were 
isolated by limiting dilution and grown in complete RPMI 1640 medium 10 % FCS (R10).  
 
L-selectin shedding 
ADAM17ΔZn/ΔZn, ADAM17WT, L∆P and C57BL/6 mice were injected intraperitoneally with 10 µg 
of SEB (Sigma-Aldrich). After 4h, pooled peripheral lymph nodes (inguinal, brachial, and 
axillary) were collected and stained for L-selectin and Vβ8 25.  
 
C57BL/6 mice were injected intravenously with 2 x 106 CD8+ T-cells co-expressing the F5 
transgenic TCR and either wildtype (F5/B6) or LΔP L-selectin (F5/LΔP). Next day, mice were 
injected intraperitoneally with 2 x 106 plaque-forming units (pfu) of recombinant vaccinia virus, 
expressing the nucleoprotein peptide ASNENMDAM (NP68) from influenza A strain E61-13-
H17 (vaccNP). Draining mediastinal lymph nodes were harvested at 24h and 48h and 
analyzed for donor F5 CD8+ T-cell expression of L-selectin and CD69 3.  
 
Blood was collected from the tail veins of ADAM17ΔZn/ΔZn, ADAM17WT, L∆P, and C57BL/6 mice 
directly into heparinized capillary tubes (Sigma-Aldrich). Whole blood (40 µl) was incubated 
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with 300 nM PMA dissolved in DMSO or an equivalent volume of DMSO as contro for 45 
minutes at 37 C. Red blood cells were then lysed, and L-selectin expression quantified by 
flow cytometry. Plasma was collected by centrifugation. Soluble L-selectin was quantified by 
ELISA 15 or by using a Mouse sL-Selectin/CD62L Quantikine ELISA Kit (R & D Systems).  
 
Basal and PMA-induced L-selectin shedding was measured in lymph node cells, resuspended 
at 5 x 107/ml in RPMI 1640, 1 % FCS (R1). Aliquots of 50 µl (2.5 x 106 cells) were incubated 
for 1h at 4 °C or 37 °C in the presence of 300 nM PMA and/or the broad spectrum ADAM/MMP 
inhibitor Ro 31-9790 (both dissolved in DMSO) or an equivalent volume of DMSO as control  
15. T-cells were analysed for cell surface L-selectin by flow cytometry, and supernatants 
analysed for soluble L-selectin by ELISA.  
 
TCR-induced shedding of L-selectin in F5/LΔP and F5/B6 mice was measured using CD8+ T-
cells resuspended in DMEM 10 % FCS, penicillin-streptomycin, L-glutamine, non-essential 
amino-acids, and β-mercaptoethanol. Splenocytes from B6 mice were pulsed with 5 µg/ml 
NP68 peptide (Peptide Synthetics) for 1h at 37 C and irradiated at 3 Gy, CD8+ T cells (2 x 
106 cells/well) were incubated with splenocytes (6 x 106 cells/well) at 37 °C in 24-well plates 
(Nunclon). Fresh complete medium supplemented with 360 IU/ml hrIL-2 was added on day 2. 
Cells were harvested as indicated, stained for CD8 and L-selectin by flow cytometry. 
 
TCR-induced L-selectin shedding in MOLT-3 cells was examined in response to HLA-A2+ C1R 
B cells pulsed with SLYNTVATL (SLY) peptide (Eurofins). MOLT-3 cells and C1R cells were 
rested overnight at 0.9 x 106 cells/ml in RPMI 1640 2 % FCS (R2). The following day, C1R 
cells were resuspended at 0.5 x 106 cells/ml in the absence or presence of SLY peptide in R2 
and distributed at 0.5 x 105 cells/well in 96-well U-bottomed plates. Cells were incubated for 
1h at 37 °C and washed in R2. MOLT-3 cells were resuspended at 1.5 x 106 cells/ml and 
added to C1R cells at a ratio of 3:1. The plates were incubated for 1h at 37 °C. To study the 
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effect of shedding inhibitors, MOLT-3 cells were pre-incubated with GW, GI, or D1(A12) 29 for 
30 minutes, added to SLY peptide-pulsed C1R cells in R2 containing inhibitors. Cells were 
washed, stained, and analysed by flow cytometry. 
 
TCR-induced T cell proliferation  
To assess the impact of L-selectin proteolysis on CD8+ T cell proliferation, 107 naïve F5/B6 or 
F5/LΔP CD8+ T-cells were resuspended in 1 ml of PBS and labelled with 5 μM CFSE for 10 
minutes at room temperature in the dark. The reaction was quenched by adding 10 ml of ice-
cold FCS. Cells were then washed extensively in ice-cold PBS, resuspended in PBS, and 
injected intravenously at 2 x 106 cells/mouse. After 24h, mice were inoculated intraperitoneally 
with 2 x 106 pfu vaccNP. Lymphoid tissues were harvested analysed for donor cell proliferation 
by quantification of CFSE dilution on days 1/2 post-infection. 
 
Virus-specific CD8+ T-cell proliferation was also assessed via incorporation of 5-ethynyl-2-
deoxyuridine (EdU) (Life Technologies). Mice were injected intraperitoneally with 1 mg of EdU. 
Organs were harvested the following day and processed as single-cell suspensions. Cells 
were stained for extracellular markers, fixed with 4 % formaldehyde, permeabilized in saponin 
buffer, and analysed for incorporation of EdU using a Click-it Plus EdU Alexa Fluor 647 Flow 
Cytometry Assay Kit (Life Technologies). 
 
CD8+ T-cell proliferation in response to peptide antigen stimulation was assessed via CFSE 
dilution. Naïve F5/B6 or F5/LΔP CD8+ T-cells were labelled with 2 μM CFSE, washed 
extensively in ice-cold PBS, resuspended in complete DMEM, and plated at 2 x 106 cells/well 
in 24-well plates (Nunclon). Splenocytes from F5/B6 mice were pulsed with 5 µg/ml NP68 
peptide (Peptide Synthetics) for 1h at 37 °C, irradiated at 3 Gy and added at 6 x 106 cells/well. 
The plates were then incubated at 37 °C. Fresh complete medium supplemented with 360 
IU/ml hrIL-2 was added on day 2. Cells were harvested as indicated and CFSE dilution was 
analyzed by flow cytometry. 
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In some experiments, F5 homozygous CD8+ T cells43 were cultured with NP68 peptide pulsed 
splenocytes or with 200 µg/ml of anti-CD3 (145.2C11; BD Biosciences) and 100 µg/ml anti-
CD28 (37.51 BD Biosciences), culture media supplemented with IL2 plus 3 µM GI, 3 µM GW 
or equivalent volume of vehicle control (DMSO) on day 2 and CD8+ T cells analysed for CD25 
expression on day 3.  
 
Flow cytometry 
For surface staining, cells were washed in PBS 2 % FCS, labelled with Live/Dead Fixable 
Aqua (Life Technologies), washed in PBS 2 % FCS, and blocked with PBS 2% FCS containing 
5 % rat serum. Cells were stained with relevant antibodies for 30 minutes at 4–8 °C, washed 
in PBS 2 % FCS, fixed with 4 % paraformaldehyde, and resuspended after a wash in 200 μl 
PBS 2 % FCS. Samples were acquired using a FACS Canto II flow cytometer (BD 
Biosciences) and CytoCount beads were used to quantify cell numbers, according to the 
manufacturer’s instructions (DakoUK Ltd, Ely, UK).  
 
The following antibodies were used to stain mouse T-cells: anti-Vβ11-FITC (KT-11), anti-CD8-
PerCPCy5.5 (53-6.7), anti-CD25-Pacific blue (JES6-5H4) anti-CD44-APCCy7 (IM7), anti-
CD62L-biotin, anti-CD62L-FITC, or anti-CD62L-PECy7 (MEL-14), anti-CD69-APC (H1.2F3), 
anti-CD90.1-PECy7 (OX-7), anti-CD90.2/Thy1.2-Pacific Blue (53-2.1), and anti-CD90.2-Alexa 
Fluor 488 (30-H12) (BioLegend); anti-Vβ8-FITC (F23.1) (BD Biosciences); anti-CCR7-APC 
(4B12) (eBioscience); and anti-TCR-PE (H57-597) (Southern Biotechnology). Fluorescence 
minus one (FMO) controls were used to detect spreading error. The following antibodies were 
used to stain human T-cells: anti-CD62L-PE (Dreg 56) with isotype control P3.6.2.8.1-PE 
(IgG1, κ) (eBioscience); and anti-Vβ5a-FITC (1C1) with isotype control MOPC-31C-FITC 
(IgG1, κ) (BD Biosciences). C1R cells in mixed cultures were identified using anti-CD19-APC 
(H1B18) (BD Biosciences) with isotype control 11711-APC (IgG1, κ) (R & D Systems). L-
selectin expression was calculated relative to vehicle-treated cells after subtracting the isotype 
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or FMO median fluorescence intensity as follows: % L-selectin = [(MFI sample – MFI isotype 
or FMO) / (MFI untreated cells – MFI isotype or FMO) x 100]. 
 
For intracellular staining, F5 transgenic CD8+ T-cells were incubated alone or restimulated 
with 2 μg/ml NP68 peptide for 5h in the presence of anti-CD107a-FITC (BioLegend) and 2 
μg/ml brefeldin A (Sigma-Aldrich), supplemented after 1h with 0.7 μg/ml monensin (BD 
Biosciences). Cells were then surface stained, fixed and permeabilized in saponin buffer 
containing 4 % paraformaldehyde for 10min at RT, and stained intracellularly with the following 
antibodies for 20min at RT: anti-IFN-γ-PerCPCy5.5 (XMG1.2) (Biolegend); and anti-TNF-α-
PECy7 (TN3-19) and anti-IL-2-eFluor 450 (JES6-5H4) (eBioscience). The cells were then 
washed in PBS 2 % FCS, fixed with 4 % paraformaldehyde, and analyzed by flow cytometry. 
Data were analyzed with FlowJo version 9.7.6 (Tree Star).  
 
Statistical analysis  
The number of animals and replicates are indicated in each figure legend. All data are 
presented as mean ± SEM. Statistical analyses were performed using Prism software Mac 
version 7 (GraphPad) as detailed in figure legends. Figures were prepared using FlowJo 
software (Treestar Inc), Prism 7 (GraphPad Software Inc.), MS Powerpoint and Adobe 
Illustrator. Investigators were blinded to the group allocation during the experiment and drug 
treatment whenever possible.  
  
21 
 
References 
1 Chao, C. C., Jensen, R. & Dailey, M. O. Mechanisms of L-selectin regulation by 
activated T cells. J Immunol 159, 1686-1694. (1997). 
2 Masopust, D. & Schenkel, J. M. The integration of T cell migration, differentiation and 
function. Nature reviews. Immunology 13, 309-320, doi:10.1038/nri3442 (2013). 
3 Mohammed, R. N. et al. L-selectin Is Essential for Delivery of Activated CD8(+) T 
Cells to Virus-Infected Organs for Protective Immunity. Cell reports 14, 760-771, 
doi:10.1016/j.celrep.2015.12.090 (2016). 
4 Nishijima, K. et al. Costimulation of T-cell proliferation by anti-L-selectin antibody is 
associated with the reduction of a cdk inhibitor p27. Immunology 116, 347-353 
(2005). 
5 Brenner, B. et al. L-selectin activates the Ras pathway via the tyrosine kinase p56lck. 
Proceedings of the National Academy of Sciences of the United States of America 
93, 15376-15381 (1996). 
6 Chen, C. et al. c-Abl is required for the signaling transduction induced by L-selectin 
ligation. Eur J Immunol 37, 3246-3258, doi:10.1002/eji.200737221 (2007). 
7 Seth, A., Gote, L., Nagarkatti, M. & Nagarkatti, P. S. T-cell-receptor-independent 
activation of cytolytic activity of cytotoxic T lymphocytes mediated through CD44 and 
gp90MEL-14. Proc Natl Acad Sci U S A 88, 7877-7881 (1991). 
8 Kilian, K., Dernedde, J., Mueller, E. C., Bahr, I. & Tauber, R. The interaction of 
protein kinase C isozymes alpha, iota, and theta with the cytoplasmic domain of L-
selectin is modulated by phosphorylation of the receptor. The Journal of biological 
chemistry 279, 34472-34480, doi:10.1074/jbc.M405916200 (2004). 
9 Le Gall, S. M. et al. ADAMs 10 and 17 represent differentially regulated components 
of a general shedding machinery for membrane proteins such as transforming growth 
factor alpha, L-selectin, and tumor necrosis factor alpha. Mol Biol Cell 20, 1785-1794 
(2009). 
10 Peschon, J. J. et al. An essential role for ectodomain shedding in mammalian 
development. Science 282, 1281-1284 (1998). 
11 Li, Y., Brazzell, J., Herrera, A. & Walcheck, B. ADAM17 deficiency by mature 
neutrophils has differential effects on L-selectin shedding. Blood 108, 2275-2279 
(2006). 
12 Yan, I. et al. ADAM17 controls IL-6 signaling by cleavage of the murine IL-6Ralpha 
from the cell surface of leukocytes during inflammatory responses. Journal of 
leukocyte biology 99, 749-760, doi:10.1189/jlb.3A0515-207R (2016). 
13 Link, M. A. et al. The role of ADAM17 in the T-cell response against bacterial 
pathogens. PloS one 12, e0184320, doi:10.1371/journal.pone.0184320 (2017). 
14 Li, N. et al. Metalloproteases regulate T-cell proliferation and effector function via 
LAG-3. The EMBO journal 26, 494-504, doi:10.1038/sj.emboj.7601520 (2007). 
15 Galkina, E. et al. L-selectin shedding does not regulate constitutive T cell trafficking 
but controls the migration pathways of antigen-activated T lymphocytes. Journal of 
Experimental Medicine. 198, 1323-1335 (2003). 
16 Tu, L. et al. A functional role for circulating mouse L-selectin in regulating 
leukocyte/endothelial cell interactions in vivo. J Immunol 169, 2034-2043 (2002). 
17 Venturi, G. M. et al. Leukocyte migration is regulated by L-selectin endoproteolytic 
release. Immunity. 19, 713-724 (2003). 
18 Ebsen, H., Schroder, A., Kabelitz, D. & Janssen, O. Differential surface expression of 
ADAM10 and ADAM17 on human T lymphocytes and tumor cells. PloS one 8, 
e76853, doi:10.1371/journal.pone.0076853 (2013). 
19 Troeberg, L. et al. E. coli expression of TIMP-4 and comparative kinetic studies with 
TIMP-1 and TIMP-2: insights into the interactions of TIMPs and matrix 
metalloproteinase 2 (gelatinase A). Biochemistry 41, 15025-15035 (2002). 
22 
 
20 Apte, S. S., Olsen, B. R. & Murphy, G. The gene structure of tissue inhibitor of 
metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene 
family. The Journal of biological chemistry 270, 14313-14318 (1995). 
21 Amour, A. et al. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. 
FEBS Lett 473, 275-279 (2000). 
22 Borland, G., Murphy, G. & Ager, A. Tissue inhibitor of metalloproteinases-3 inhibits 
shedding of L-selectin from leukocytes. Journal of Biological Chemistry 274, 2810-
2815 (1999). 
23 Scheuplein, F. et al. NAD+ and ATP released from injured cells induce P2X7-
dependent shedding of CD62L and externalization of phosphatidylserine by murine T 
cells. J Immunol 182, 2898-2908 (2009). 
24 Galkina, E. et al. T lymphocyte rolling and recruitment into peripheral lymph nodes is 
regulated by a saturable density of L-selectin (CD62L). Eur J Immunol 37, 1243-1253 
(2007). 
25 Miethke, T., Wahl, C., Holzmann, B., Heeg, K. & Wagner, H. Bacterial superantigens 
induce rapid and T cell receptor V beta-selective down-regulation of L-selectin 
(gp90Mel-14) in vivo. J Immunol 151, 6777-6782 (1993). 
26 Chen, A., Engel, P. & Tedder, T. F. Structural requirements regulate endoproteolytic 
release of the L-selectin (CD62L) adhesion receptor from the cell surface of 
leukocytes. Journal of Experimental Medicine 182, 519-530 (1995). 
27 Ludwig, A. et al. Metalloproteinase inhibitors for the disintegrin-like 
metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and 
phorbol ester-inducible shedding of cell surface molecules. Comb Chem High 
Throughput Screen 8, 161-171 (2005). 
28 Preece, G., Murphy, G. & Ager, A. Metalloproteinase-mediated regulation of L-
selectin levels on leucocytes. Journal of Biological Chemistry 271, 11634-11640 
(1996). 
29 Tape, C. J. et al. Cross-domain inhibition of TACE ectodomain. Proc Natl Acad Sci U 
S A 108, 5578-5583, doi:10.1073/pnas.1017067108 (2011). 
30 Chiu, C. et al. Early acquisition of cytolytic function and transcriptional changes in a 
primary CD8+ T-cell response in vivo. Blood 109, 1086-1094, doi:10.1182/blood-
2006-03-011643 (2007). 
31 Stauber, D. J., Debler, E. W., Horton, P. A., Smith, K. A. & Wilson, I. A. Crystal 
structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine 
receptor. Proc Natl Acad Sci U S A 103, 2788-2793, doi:10.1073/pnas.0511161103 
(2006). 
32 Sheu, B. C. et al. A novel role of metalloproteinase in cancer-mediated 
immunosuppression. Cancer Res 61, 237-242 (2001). 
33 Hickman, H. D. et al. Chemokines control naive CD8+ T cell selection of optimal 
lymph node antigen presenting cells. J Exp Med 208, 2511-2524, 
doi:10.1084/jem.20102545 (2011). 
34 Kansas, G. S., Ley, K., Munro, J. M. & Tedder, T. F. Regulation of leukocyte rolling 
and adhesion to high endothelial venules through the cytoplasmic domain of L-
selectin. Journal of Experimental Medicine 177, 833-838 (1993). 
35 Rzeniewicz, K. et al. L-selectin shedding is activated specifically within transmigrating 
pseudopods of monocytes to regulate cell polarity in vitro. Proc Natl Acad Sci U S A 
112, E1461-1470, doi:10.1073/pnas.1417100112 (2015). 
36 Laszik, Z. et al. P-selectin glycoprotein ligand-1 is broadly expressed in cells of 
myeloid, lymphoid, and dendritic lineage and in some nonhematopoietic cells. Blood 
88, 3010-3021 (1996). 
37 Richards, H., Longhi, M. P., Wright, K., Gallimore, A. & Ager, A. CD62L (L-Selectin) 
Down-Regulation Does Not Affect Memory T Cell Distribution but Failure to Shed 
Compromises Anti-Viral Immunity. J Immunol 180, 198-206 (2008). 
23 
 
38 Sallusto, F., Lenig, D., Forster, R., Lipp, M. & Lanzavecchia, A. Two subsets of 
memory T lymphocytes with distinct homing potentials and effector functions. Nature 
401, 708-712. (1999). 
39 Graef, P. et al. Serial transfer of single-cell-derived immunocompetence reveals 
stemness of CD8(+) central memory T cells. Immunity 41, 116-126, 
doi:10.1016/j.immuni.2014.05.018 (2014). 
40 Tian, G. et al. CD62L+ NKT cells have prolonged persistence and antitumor activity 
in vivo. The Journal of clinical investigation 126, 2341-2355, doi:10.1172/JCI83476 
(2016). 
41 Cole, D. K. et al. Dual Molecular Mechanisms Govern Escape at Immunodominant 
HLA A2-Restricted HIV Epitope. Front Immunol 8, 1503, 
doi:10.3389/fimmu.2017.01503 (2017). 
42 Demaison, C. et al. High-level transduction and gene expression in hematopoietic 
repopulating cells using a human immunodeficiency [correction of imunodeficiency] 
virus type 1-based lentiviral vector containing an internal spleen focus forming virus 
promoter. Human gene therapy 13, 803-813, doi:10.1089/10430340252898984 
(2002). 
43 Watson, H. A. et al. Purity of transferred CD8(+) T cells is crucial for safety and 
efficacy of combinatorial tumor immunotherapy in the absence of SHP-1. 
Immunology and cell biology 94, 802-808, doi:10.1038/icb.2016.45 (2016). 
 
  
24 
 
Study Approval  
Animal experimental protocols adhered to local and national guidelines.  Animal work was 
conducted inside the designated establishment at Cardiff University which fully complies to 
the Home Office Code of Practice for the Housing and Care of Animals Bred, Supplied or Used 
for Scientific Purposes pursuant to the Animal (Scientific Procedures) Act, 1986. All studies 
were approved by the Animal and Welfare Ethical Review Body at Cardiff University and 
conducted under the Animal (Scientific Procedures) Act, 1986.  
 
Acknowledgments 
We thank Roy Black and Jacques Peschon for C57BL/6 ADAM17+/ΔZn mice and blood from 
DBA ADAM17 ΔZn/ΔZn and ADAM17 sufficient mice, Tom Tedder for L-selectin knockout mice 
and ΔM-N L-selectin cDNA, Victor Tybulewicz for advice on radiation chimeras, Miriam Vigar 
for growing vaccinia virus, Sophie Reed for assistance with experiments and staff at the 
Francis Crick Institute and Cardiff University for mouse care. This work was supported by the 
Ministry of Kurdistan Regional Government, Iraq (RNM), PhD studentships from the Medical 
Research Council, UK (SCW), the Biotechnology and Biological Sciences Research Council, 
UK (EKY) and Cardiff University (AN, ORM). HAW, JO and RRPD were funded by Wellcome 
Trust grant 094511/Z/10/Z, Medical Research Council UK grant MR/L008742/1, Health and 
Care Research Wales grant CA05 and Cancer Research UK grant C42412/A24416 to AA. GD 
and JSB were funded by Wellcome Trust grant 100327/Z/12/Z and Biotechnology and 
Biological Sciences Research Council grant BB/H001085/1 to Andrew K Sewell; we thank the 
generous support of this research by Professor Sewell. DAP is a Wellcome Trust Senior 
Investigator (100326Z/12/Z).  
 
Author contributions 
RNM, SCW, EKY, EVG, RJM, VK, and AA conceived the study; RNM, SCW, EKY, EVG, GP, 
AN, HAW, JO, RRPD, ORM and GD performed experiments; KL and KLM assisted with flow 
cytometry; JSB, DAP, LT, MK, GM and HN provided critical reagents; AA supervised the study 
25 
 
with critical input from VK; RNM, SCW, EKY and AA wrote the manuscript with contributions 
from all authors. 
 
Additional Information 
The authors declare no financial or non-financial conflicts of interest. 
  
26 
 
 Figures and  Legends 
Figure 1. ADAM17-independent shedding of L-selectin in T-cells. 
(A-C) ADAM17 deficient mouse strains used; (A) RAG-1-/- radiation chimeras for L-selectin 
expression in isolated T lymphocytes, (B) L-selectin-/- radiation chimeras and (C) DBA mice 
for soluble L-selectin in blood. (D–G) Constitutive and activation induced shedding of L-
selectin. (D, E) Lymphocytes from ADAM17-sufficient (ADAM17WT) or ADAM17-deficient 
(ADAM17ΔZn/ΔZn) RAG-1-/- chimeras were incubated in the presence of 30 µM Ro 31-9790 
and/or 300 nM PMA or vehicle controls (Control) and analyzed for (D) T cell expression of L-
selectin (CD62L) (see Fig 1S for gating of CD62L positive T-cells) and (E) shed L-selectin. (F, 
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G) Lymphocytes from B6 and L∆P mice were incubated in the presence of 30 µM Ro 31-9790 
and/or 300 nM PMA or vehicle controls (Control) and analyzed for (F) T cell expression of L-
selectin (CD62L) and (G) shed L-selectin. (H) Soluble L-selectin in plasma from ADAM17WT 
or ADAM17ΔZn/ ΔZn L-selectin-/- chimeras, adult B6, adult LΔP,  3-week old DBA mice and 3-
week old ADAM17ΔZn/ ΔZn DBA mice was analyzed by ELISA. (I) Soluble L-selectin released 
by ADAM17-deficient lymphocytes in the absence or presence of 30 µM Ro 31-9790, 1 µM 
TIMP1, or 1 µM TIMP3 was analyzed by ELISA. Bar charts show mean±SEM (n = 4–10 in A–
D, n = 4 in F). Symbols in panel H show data from individual mice, and horizontal bars indicate 
mean values. Statistical analysis used two-way ANOVA with Tukey’s post-hoc test in panels 
D-G, student’s t test in panel H and one-way ANOVA in panel I. ***P < 0.001. 
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Figure 2. TCR-induced L-selectin downregulation on T-cells requires ADAM17. 
(A–D) ADAM17WT, ADAM17ΔZn/ΔZn RAG-1-/- chimeras (A, B), B6 and L∆P mice (C, D) were 
injected intraperitoneally with 10 µg of SEB. After 4h, L-selectin expression on Vβ8+ and Vβ8– 
T cells isolated from lymph nodes was determined by flow cytometry. Representative 
histograms show L-selectin expression on Vβ8+ (dashed line) and Vβ8– (solid line) T-cells 
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versus an isotype control (control) (A, C). Scatter plots show mean ± SEM (n = 3–5 mice) (B, 
D). (E–G) Cell surface levels of L-selectin on flow-sorted 868 TCR+ Molt3 cells expressing 
wildtype (E-G) or ΔM-N (E) L-selectin were determined by flow cytometry after incubation for 
1h with SLY peptide-pulsed antigen-presenting cells at a ratio of 1:3. SLY peptide stimulation 
was conducted in the absence of inhibitors (E), the presence of selective ADAM10 inhibitor GI 
or dual ADAM10/ADAM17 inhibitor GW (F), or the presence of blocking ADAM17 antibody 
D1(A12) or control human IgG (G). (H) TCR downregulation on 868 TCR+ Molt3 cells was 
determined by flow cytometry in the absence or presence of 30 μM GW. Percentages for L-
selectin and TCR expression were obtained by subtracting the median fluorescence intensity 
(MFI) of the isotype-matched control from the MFI of each sample and normalizing to non-
incubated cells stored on ice (100 % expression). Cells were gated as live, single lymphocytes, 
and antigen-presenting cells were excluded by dumping CD19. Red dashed lines indicate 100 
% expression (E–H) and maximal downregulation (F, G). Symbols in panels B and D show 
data from individual mice, and horizontal bars indicate means. Results in panels E-H are mean 
± SEM (n= 3-5). Statistical analysis used unpaired Student’s 2-tailed t test. *P < 0.05; ***P < 
0.001. 
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Figure 3. TCR-induced L-selectin shedding promotes the clonal expansion of effector 
T cells in virus-infected mice.  
(A) Thy1.2 CD8+ T cells co-expressing the F5 transgenic TCR and either wildtype (F5/B6) or 
shedding-resistant (F5/L∆P) L-selectin were labelled with CFSE and injected intravenously 
into naïve Thy1.1 mice. After 24 hours, mice were inoculated intraperitoneally with vaccNP. 
Non-draining inguinal lymph nodes (ndLN) and draining mediastinal lymph nodes (dLN) were 
harvested at days 1 and 2 after virus challenge, and donor cells were analyzed for CD69 
expression and dilution of CFSE. (B) Bar charts show CD69+ F5/B6 and F5/L∆P CD8+ T cells 
in the draining mediastinal lymph nodes at days 1 and 2 post-infection (mean ± SEM, n = 3). 
(C) Representative histograms show CFSE label in F5/B6 and F5/LΔP CD8+ T cells in the 
draining mediastinal lymph nodes of uninfected mice (control) and infected mice at day 2 after 
inoculation with vaccNP. Unlabelled cells are shown as light grey histograms. (D) Scatter plots 
of division indices for F5/B6 and F5/LΔP CD8+ T cells at day 2 after infection with vaccNP. 
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Symbols represent individual mice, and lines indicate mean values. (E-F) Bar charts show 
total numbers of donor F5/B6 and F5/LΔP CD8+ T cells in draining mediastinal lymph nodes 
and non-draining inguinal lymph nodes at days 1 (E) and 2 (F) after infection with vaccNP. 
Uninfected mice injected with F5 transgenic CD8+ T cells are shown for comparison (control). 
Results are shown as mean ± SEM (n = 3). Statistical significance was assessed using 
unpaired Student’s 2-tailed t test in panels D and two-way ANOVA with Tukey’s post-hoc test 
in panel E. *P < 0.05; **P < 0.01. 
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Figure 4. TCR-induced L-selectin shedding promotes CD8+ T cell proliferation in vitro. 
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(A) Representative histograms show CD69 expression on F5/B6 and F5/LΔP CD8+ T cells 
over time after stimulation with cognate peptide-pulsed antigen-presenting cells. Numbers 
indicate percent CD69+ cells. Grey histograms depict staining with an isotype control antibody. 
(B) Bar charts show percent CD69+ F5/B6 and F5/L∆P CD8+ T cells (mean ± SEM, n = 3). (C) 
Representative histograms show CFSE label in F5/B6 and F5/LΔP CD8+ T cells at days 0, 4, 
and 5 after stimulation in vitro with peptide-pulsed antigen-presenting cells. (D) Scatter plots 
of division indices for F5/B6 and F5/LΔP CD8+ T cells at days 4 and 5 post-activation in vitro. 
(E) Density plots show up-regulation of CD25 by F5/B6 and F5/LDP CD8+ T cells at day 3 
post-activation in vitro. (F) Bar charts show CD25 expression by F5/B6 and F5/LΔP CD8+ T 
cells at days 0, 1, 2, 3, 4, and 5 post-activation in vitro (mean ± SEM, n = 5). Statistical 
significance was assessed using unpaired Student’s 2-tailed t test in panels D and F. *P < 
0.05; ***P < 0.001.  
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Supplemental Information 
 
Supplementary Figure 1, related to Figure 1. Effect of ADAM17 on L-selectin expression 
by T-cells under homeostatic and activating conditions.  
ADAM17-sufficient (ADAM17WT) and ADAM17-deficient (ADAM17ΔZn/ΔZn) T-cells harvested 
from peripheral lymph nodes of RAG-1-deficient haematopoietic stem cell chimeric mice were 
incubated at 4 °C or 37 °C in the absence or presence of 300nM PMA. Cell surface expression 
of L-selectin (CD62L) was analyzed by flow cytometry. Representative histograms show 
overlays of treatments and gating of CD62L positive T-cells. 
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Supplementary Table 1. Genotype of mouse strains used. 
  
Mouse ID 
ADAM
17 
Background  F5 TCR 
Wildtype 
L-
selectin 
LΔP Thy 
ADAM17WT 
+/+ or 
+/- 
B6 RAG-1-/- 
chimera 
none +/+ none Thy1.2 
ADAM17ΔZn/Δ
Zn -/-
 B6 RAG-1
-/- 
chimera 
none +/+ none Thy1.2 
ADAM17WT 
+/+ or 
+/- 
B6 L-selectin-
/-chimera 
none +/+ none Thy1.2 
ADAM17ΔZn/Δ
Zn -/-
 B6 L-selectin
-
/-chimera 
none +/+ none Thy1.2 
DBA +/+ DBA none +/+ none Thy1.2 
ΔZn/ ΔZn 
DBA 
-/- DBA none +/+ none Thy1.2 
F5/B6 +/+ B6 
hemizygou
s 
+/+ none Thy1.2 
F5/LΔP +/+ B6 
hemizygou
s 
-/- 
hemi- 
zygous 
Thy1.2 
LΔP +/+ B6 none -/- 
hemi- 
zygous 
Thy1.2 
C57BL/6 
(B6) 
+/+ B6 none +/+ none Thy1.2 
Thy1.1 +/+ B6 none +/+ 
none 
none 
Thy1.1 
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Supplementary Table 2. Genotype of T cells used. 
 
Cell line ID 
Specie
s 
Cell type TCR 
Wildtype L-
selectin 
Transgenic L-
selectin 
genotype 
L-selectin 
 
Human 
 
Molt3 868 -/- 
Wildtype human L-
selectin 
ΔM-N Human Molt3 868 -/- 
Shedding-resistant 
human L-selectin 
F5/B6 Mouse 
CD8+ 
naïve or 
CTL 
F5 +/+ none 
F5/LΔP Mouse 
CD8+ 
naïve or 
CTL 
F5 -/- 
Shedding-resistant 
mouse L-selectin 
